This article discusses the Eli Lilly and Company dispute with Hospira over a generic version of Lilly’s Gemzar®, a cancer drug, with a focus on Lilly’s decision to bring this case to the International Trade Commission (ITC). The ITC is not a typical forum for pharmaceutical companies involved in IP cases. The article states that “in a novel strategy to beat back generic competition to its blockbuster drug Gemzar®, Lilly has turned to the ITC,” a forum that deals with patent disputes in a time sensitive manner. Lilly claims that Hospira has conspired with other drug companies to make a generic form of Gemzar® using a process that infringes it’s patent. Lilly is represented by Finnegan.